{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:02:39Z","timestamp":1789614159754,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.breast.2026.104888","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T06:50:43Z","timestamp":1784962243000},"page":"104888","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world implementation of pertuzumab from 2013 to 2023 for de Novo HER2-positive metastatic breast cancer in the Netherlands: a population-based study"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5719-0738","authenticated-orcid":false,"given":"Nan","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra M.E.","family":"Geurts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4550-3715","authenticated-orcid":false,"given":"Ingeborg J.H.","family":"Vriens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6279-9917","authenticated-orcid":false,"given":"Ren\u00e9e","family":"Visserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6431-3538","authenticated-orcid":false,"given":"Thiemo J.A.","family":"van Nijnatten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"Smidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8041-2720","authenticated-orcid":false,"given":"Adri C.","family":"Voogd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janneke","family":"Verloop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivianne C.G.","family":"Tjan-Heijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.breast.2026.104888_bib1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMp1510443","article-title":"Trends in metastatic breast and prostate Cancer--Lessons in cancer dynamics","volume":"373","author":"Welch","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.breast.2026.104888_bib2","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1056\/NEJMoa1206809","article-title":"Effect of three decades of screening mammography on breast-cancer incidence","volume":"367","author":"Bleyer","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.breast.2026.104888_bib3","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.breast.2026.104888_bib4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","volume":"14","author":"Swain","year":"2013","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.breast.2026.104888_bib5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-Positive breast cancer","volume":"380","author":"von","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.breast.2026.104888_bib6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10549-022-06700-6","article-title":"Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer","volume":"196","author":"File","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.breast.2026.104888_bib7","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.breast.2026.104888_bib8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10549-020-05614-5","article-title":"Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes","volume":"181","author":"Gong","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"10.1016\/j.breast.2026.104888_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.2140","article-title":"Practice patterns and outcomes of novel targeted agents for the treatment of ERBB2-Positive metastatic breast cancer","volume":"7","author":"Ethier","year":"2021","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104888_bib10","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104888_bib11","doi-asserted-by":"crossref","first-page":"viii121","DOI":"10.1093\/annonc\/mdy272.357","volume":"29","author":"Loibl","year":"2018","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104888_bib12","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104888_bib13","article-title":"Trastuzumab deruxtecan plus pertuzumab for HER2-Positive metastatic breast cancer","author":"Tolaney","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.breast.2026.104888_bib14","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-Positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104888_bib15","article-title":"HER2CLIMB-05: a phase III study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as first-line maintenance therapy for HER2+ metastatic breast cancer","author":"Dieras","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.breast.2026.104888_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx187","article-title":"Real-world data for clinical evidence generation in oncology","volume":"109","author":"Khozin","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"34","key":"10.1016\/j.breast.2026.104888_bib17","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2018.33.e213","article-title":"Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records","volume":"33","author":"Kim","year":"2018","journal-title":"J Kor Med Sci"},{"key":"10.1016\/j.breast.2026.104888_bib18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.breast.2021.09.011","article-title":"Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database","volume":"60","author":"Annonay","year":"2021","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.breast.2026.104888_bib19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10549-021-06103-z","article-title":"Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry","volume":"188","author":"Kaufman","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.breast.2026.104888_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/pds.5792","article-title":"Comorbidity influence in observational studies: why ignore the real world?","volume":"33","author":"Kiri","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.breast.2026.104888_bib21","author":"Nederland"},{"issue":"19","key":"10.1016\/j.breast.2026.104888_bib22","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.280.19.1690","article-title":"What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes","volume":"280","author":"Zhang","year":"1998","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.breast.2026.104888_bib23","first-page":"1","article-title":"Mice: multivariate imputation by chained equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Software"},{"issue":"9","key":"10.1016\/j.breast.2026.104888_bib24","first-page":"1322","article-title":"Missing data in clinical research: a tutorial on multiple imputation","volume":"37","author":"Austin","year":"2021","journal-title":"Can J Cardiol"},{"issue":"2","key":"10.1016\/j.breast.2026.104888_bib25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10549-023-07235-0","article-title":"Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry","volume":"205","author":"Geurts","year":"2024","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.breast.2026.104888_bib26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10549-022-06832-9","article-title":"Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry","volume":"198","author":"Ibragimova","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104888_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115475","article-title":"Overall survival of patients with de Novo HER2-positive metastatic breast cancer in the Netherlands from 2008 to 2017: a population-based cohort study of systemically treated patients","volume":"222","author":"Ding","year":"2025","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.breast.2026.104888_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100114","article-title":"Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort","volume":"6","author":"Grinda","year":"2021","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.breast.2026.104888_bib29","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ijc.35448","article-title":"Real-world comparative effectiveness and safety of Pertuzumab in patients with HER2+ metastatic breast cancer: a pan-Canadian population-based cohort study","volume":"157","author":"Mu\u00f1oz","year":"2025","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.breast.2026.104888_bib30","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO-ESMO International consensus guidelines for advanced breast cancer (ABC 4)","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann Oncol"},{"issue":"26","key":"10.1016\/j.breast.2026.104888_bib31","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.23.00933","article-title":"Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update","volume":"41","author":"Dale","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104888_bib32","series-title":"Choosing wisely","year":"2021"},{"issue":"1","key":"10.1016\/j.breast.2026.104888_bib33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10549-013-2710-z","article-title":"Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)","volume":"142","author":"Miles","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.breast.2026.104888_bib34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(18)30083-4","article-title":"Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the elderly task force\/breast cancer group","volume":"19","author":"Wildiers","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.breast.2026.104888_bib35","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1158\/1055-9965.EPI-24-0144","article-title":"Sociodemographic disparities in HER2+ breast cancer Trastuzumab receipt: an English population-based study","volume":"33","author":"Norris","year":"2024","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9","key":"10.1016\/j.breast.2026.104888_bib36","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3390\/cancers17091579","article-title":"Clinical, sociodemographic, and facility-related factors influencing HER2-Targeted therapy in metastatic hormone receptor-negative, HER2-Positive breast cancer","volume":"17","author":"Ajjawi","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.breast.2026.104888_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2022.102118","article-title":"Socioeconomic status and its relation with breast cancer recurrence and survival in young women in the Netherlands","volume":"77","author":"van Maaren","year":"2022","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"10.1016\/j.breast.2026.104888_bib38","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s10549-010-1250-z","article-title":"Socioeconomic differences in survival among breast cancer patients in the Netherlands not explained by tumor size","volume":"127","author":"Bastiaannet","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.breast.2026.104888_bib39","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1093\/annonc\/mdx204","article-title":"The influence of socioeconomic status and ethnicity on adjuvant systemic treatment guideline adherence for early-stage breast cancer in the Netherlands","volume":"28","author":"Kuijer","year":"2017","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104888_bib40","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1634\/theoncologist.2015-0110","article-title":"Distance as a barrier to cancer diagnosis and treatment: review of the literature","volume":"20","author":"Ambroggi","year":"2015","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.breast.2026.104888_bib41","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.breast.2026.104888_bib42","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1158\/1078-0432.CCR-22-1092","article-title":"Pertuzumab, trastuzumab, and an aromatase inhibitor for HER2-Positive and hormone receptor-positive metastatic or locally advanced breast cancer: PERTAIN final analysis","volume":"29","author":"Arpino","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.breast.2026.104888_bib43","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1158\/1078-0432.CCR-21-3435","article-title":"Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for patients with hormone receptor-positive and HER2-Positive metastatic breast cancer (SYSUCC-002)","volume":"28","author":"Hua","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104888_bib44","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1186\/1472-6963-14-469","article-title":"Factors affecting the uptake of new medicines: a systematic literature review","volume":"14","author":"Lubl\u00f3y","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.breast.2026.104888_bib45","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2023.03.013","article-title":"Defining the role of real-world data in cancer clinical research: the position of the European Organisation for research and treatment of cancer","volume":"186","author":"Saesen","year":"2023","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.breast.2026.104888_bib46","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10549-021-06178-8","article-title":"Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE registry","volume":"188","author":"Ibragimova","year":"2021","journal-title":"Breast Cancer Res Treat"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:32:34Z","timestamp":1789612354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626001980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":46,"alternative-id":["S0960977626001980"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104888","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world implementation of pertuzumab from 2013 to 2023 for de Novo HER2-positive metastatic breast cancer in the Netherlands: a population-based study","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104888","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104888"}}